CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

AIMAIM ImmunoTech Inc.

AMEX · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $0.17 · 2026-09-30
ABOUT
ExchangeAMEX
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$5.33M
CountryUSA
RECENT INSIDER TRADES
  • 2026-09-18 · Equels Thomas K (CEO & President) · BUY
  • 2026-09-17 · Equels Thomas K (CEO & President) · BUY
  • 2026-09-16 · Equels Thomas K (CEO & President) · BUY
  • 2026-09-15 · Equels Thomas K (CEO & President) · BUY
  • 2026-03-16 · Equels Thomas K (CEO & President) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders20
Shares held1,863,154
Value$570.62K
Percent of shares outstanding6.12%
As of quarter end2026-06-30
RECENT NEWS
  • AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
  • AIM ImmunoTech highlights media coverage of Ampligen antiviral potential
  • AIM ImmunoTech advances Phase 2 DURIPANC trial of Ampligen for pancreatic cancer
  • AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
  • AIM ImmunoTech highlights Ampligen's potential in pancreatic cancer
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS